drugset / Trial / NCT02367859
Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma
NaSingle-groupOpen-labelTreatment
Summary
This pilot clinical trial studies dabrafenib and trametinib in treating patients with ameloblastoma and a specific mutation (change) in the BRAF gene. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2017-07-17
- Primary completion
- 2018-11-05
- Completion
- 2019-06-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabrafenib | Small molecule | — | Oral |
| Subject | Trametinib | Small molecule | 2 mg | Oral |